#45 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
As New Hampshire’s medical cannabis program expands with 2,100 new patients, clinicians need updated evidence on efficacy and safety profiles in older populations who represent a growing segment of users. The program’s growth creates opportunities for clinical research that could establish clearer dosing guidelines and drug interaction data relevant to patients on multiple medications. Tax incentives for producers may stabilize supply chains and reduce costs, improving patient access to tested, regulated products rather than unregulated alternatives.
New Hampshire’s medical cannabis program experienced significant growth with 2,100 new patient registrations in the past year, reflecting expanding patient access and demographic shifts toward an older patient population seeking cannabis-based treatment. This expansion has regulatory and economic implications, as increased enrollment creates opportunities for cannabis-based clinical research and may enable tax incentives for licensed producers, potentially improving product availability and standardization. The aging demographic composition of New Hampshire’s patient population aligns with growing clinical interest in cannabis for conditions common in older adults, including chronic pain, nausea, and sleep disturbances, though evidence for efficacy in these populations remains limited. Clinicians should recognize that the expanding patient base and research environment may yield more rigorous clinical data to inform prescribing decisions in coming years. For clinicians evaluating cannabis for their patients, this growth signals both increased regulatory infrastructure and a potential shift toward evidence-based guidance as more research emerges from expanded state programs.
“When we see 2100 new patients enrolling in a year, most of them over 65, it tells us that older adults are finally feeling comfortable discussing cannabis with their physicians and that we’re moving past the stigma that prevented earlier adoption of this medicine for conditions like chronic pain and insomnia.”
💚 New Hampshire’s expanding medical cannabis program, with over 2,100 new patient enrollments annually, reflects growing clinical acceptance and patient interest in cannabis for symptom management, particularly among older adults. However, clinicians should recognize that program growth does not necessarily indicate robust evidence for efficacy or safety in their respective populations; enrollment expansion often outpaces rigorous comparative effectiveness research, and demographic shifts toward older patients introduce concerns about drug-drug interactions, fall risk, and cognitive effects that warrant careful individual assessment. The prospect of increased research funding and tax incentives may eventually strengthen the evidence base, but providers cannot assume that regulatory approval and market expansion translate into clear clinical guidance for their patients. In practice, clinicians should continue to engage patients interested in medical cannabis through shared decision-making frameworks, acknowledge gaps in evidence specific to their patients’ conditions, and maintain awareness of local program requirements while prioritizing baseline cognitive and functional assessments and thoughtful monitoring for adverse effects, particularly
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
